Fisetin: The Most Potent Natural Senolytic Compound (2026)

In 2018, researchers at the Mayo Clinic tested ten naturally occurring flavonoids for their ability to selectively eliminate senescent cells from human tissue. The result was unambiguous: fisetin outperformed every other compound tested, including quercetin, luteolin, and apigenin (Yousefzadeh et al., EBioMedicine, 2018; PMC6197652). That finding placed this obscure plant polyphenol at the center of one of the fastest-moving fields in aging research: senolytics.

TL;DR – Key Takeaways

• Fisetin ranked #1 among 10 flavonoids for senolytic potency in a Mayo Clinic study
• Mechanism: disrupts the PI3K/AKT/BCL-2 survival pathway that keeps "zombie cells" alive
• Multiple Phase 2 human trials are actively underway (AFFIRM-LITE, NCT03675724)
• Encapsulated fisetin achieves 26.9x greater plasma absorption than standard fisetin
• Low daily doses provide ongoing anti-inflammatory and antioxidant benefits independent of senolytics
• An effective protocol uses microencapsulated fisetin at 200mg daily with an optional monthly surge

What Senescent Cells Are and Why They Matter

A senescent cell is a cell that has sustained enough damage – from DNA breaks, telomere shortening, or oxidative stress – to permanently stop dividing, but has not died. In youth, this is protective: halting a damaged cell's division prevents it from becoming cancerous, and the cell signals the immune system for cleanup.

The problem emerges with age. Your immune system's ability to clear senescent cells declines. They accumulate. And accumulating senescent cells are not quiet – they secrete a toxic mixture of inflammatory cytokines, proteases, and growth factors called the SASP (Senescence-Associated Secretory Phenotype). The SASP damages neighboring healthy cells, promotes chronic inflammation, impairs tissue regeneration, and can even push nearby healthy cells into senescence themselves.

This was proven causally, not just by correlation. In two landmark studies, the Baker laboratory at Mayo Clinic used genetically engineered mice with a "kill switch" that could selectively eliminate senescent cells on command. In 2011, they showed that clearing senescent cells delayed cataracts, muscle wasting, and fat loss (Nature, 2011; PMID 22048312). In 2016, they demonstrated that clearing senescent cells in normal mice extended median lifespan by 17–35% (Nature, 2016; PMID 26840489).

Senescent cells are not a biomarker of aging. They are a driver of it.

How Fisetin Kills Zombie Cells

Fisetin targets what scientists call SCAPs – Senescence-Associated Anti-apoptotic Pathways. These are the survival networks that keep senescent cells alive despite being damaged and non-functional.

The primary pathway is the PI3K/AKT/BCL-2 axis. Senescent cells upregulate BCL-2 family pro-survival proteins (BCL-2, BCL-XL) to resist the apoptosis signals they would normally receive. Fisetin disrupts this: it inhibits PI3K-AKT signaling upstream of BCL-2, causing the senescent cell to lose its survival advantage and undergo programmed cell death (Zhu et al., Aging, 2017; confirmed by PMID 40259678, 2025).

The selectivity is the key. Proliferating cells and quiescent healthy cells use different survival mechanisms – they are not dependent on the PI3K/AKT/BCL-2 axis. This is why fisetin can clear senescent cells without collateral damage to healthy tissue.

The Yousefzadeh paper described this as a "hit-and-run" mechanism: brief high-dose exposure clears a cohort of senescent cells. The cells do not regenerate overnight – it takes weeks to months for a new population to accumulate.

Key Takeaway: Fisetin selectively kills senescent cells by disrupting the PI3K/AKT/BCL-2 survival pathways these "zombie cells" depend on — without harming healthy cells. In a head-to-head comparison of 10 flavonoids, fisetin was the most potent natural senolytic. It works as a "hit-and-run" mechanism: brief high-dose exposure clears senescent cells, which take weeks to months to reaccumulate.

Watch: Peter Attia and Andrew Huberman discuss longevity supplements including senolytics:

The Human Clinical Program

The science is strong but the human data is still being collected. Here is the honest state of affairs:

AFFIRM-LITE (NCT03675724) is the definitive Phase 2 human trial. Run by Dr. James Kirkland at Mayo Clinic – the world's leading senolytic researcher – it tests 20 mg/kg/day of fisetin for 2 consecutive days in adults aged 70–90. For a 75 kg person, that is 1,500 mg on each dosing day. Primary endpoints include senescence biomarkers (p16, p21), inflammatory markers, and physical function. Results have not yet been published as of March 2026.

A COVID-era safety trial in skilled nursing facilities (PMID 34375437) confirmed fisetin was well-tolerated in elderly, frail patients – an important safety signal.

A 2025 study in Aging Cell (PMC12341784) compared intermittent fisetin supplementation to genetic senescent cell clearance and ABT-263. Intermittent fisetin matched both approaches in reducing skeletal muscle senescence markers and improving grip strength in aged mice.

Additional trials are actively enrolling: fisetin for vascular function in older adults (NCT06133634), fisetin for frailty in breast cancer survivors (NCT05595499), and a new pilot trial in healthy volunteers (NCT06431932).

Safety Note: High-dose fisetin pulse protocols (1,500 mg/day) used in clinical trials are physician-guided interventions, not self-administered regimens. At daily doses of 200 mg, fisetin is well-tolerated, but if you take blood thinners or immunosuppressants, consult your doctor before starting, as fisetin has anti-inflammatory and antiplatelet properties.

The Bioavailability Problem – And the Solution

Standard unformulated fisetin has poor oral bioavailability (the proportion of a compound that actually reaches your bloodstream after you take it). It is hydrophobic, undergoes rapid first-pass metabolism in the liver, has a plasma half-life of approximately 1–1.5 hours, and is actively pumped back into the intestinal lumen by P-glycoprotein transporters.

A 2022 randomized, double-blind crossover study (PMC9574875) tested an encapsulated fisetin formulation against standard fisetin in 15 healthy volunteers. The encapsulated form achieved 26.9-fold greater plasma AUC – the largest bioavailability enhancement documented in the senolytic ingredient space. Peak blood levels were 24x higher. Detection duration extended from 2 hours to 8 hours.

This is why microencapsulated fisetin matters. The difference between a dose that can realistically engage senolytic mechanisms and one that passes through without meaningful effect is formulation technology. For more on how formulation affects every compound in this system, see Why Supplement Form Matters More Than Dose.

Key Takeaway: Standard fisetin has poor bioavailability — most passes through without reaching meaningful blood levels. Microencapsulated fisetin achieves 26.9x greater plasma exposure, making it the form to look for. The Mayo Clinic AFFIRM-LITE trial will provide definitive human efficacy data; until then, the animal data and early human safety data are genuinely strong.

Pulse Dosing vs. Daily Dosing

The clinical research uses high-dose pulse protocols – 1,500 mg for 2 days, then nothing for 28 days. This makes sense mechanistically: you clear a cohort of senescent cells, wait for a new cohort to accumulate, then clear again.

But daily fisetin at lower doses (200 mg) provides genuine benefits that are not primarily senolytic:

• NF-κB inhibition: Anti-inflammatory activity that requires ongoing exposure
• Nrf2 activation: Upregulation of endogenous antioxidant defenses (glutathione, SOD, HO-1)
• Neuroprotective effects: Fisetin crosses the blood-brain barrier and demonstrates cognitive protection in animal models

A practical protocol bridges both approaches: 200 mg daily provides continuous anti-inflammatory and antioxidant support, while an optional monthly surge (400 mg on days 1–2 of each month) provides a higher-dose pulse that moves closer to the senolytic threshold.

Fisetin works synergistically with quercetin – both target overlapping but distinct survival pathways in senescent cells. To understand how formulation affects senolytic delivery, see Bioavailability: Why Supplement Form Matters More Than Dose.

Key Takeaway: Daily fisetin at 200mg provides continuous anti-inflammatory, antioxidant, and neuroprotective benefits beyond senolytic action. For stronger senolytic pulses, consider an optional monthly surge of 400mg for 2 days. This dual approach captures both the chronic anti-inflammatory benefits and the periodic senolytic clearing.

Watch: David Sinclair's latest on aging reversal, supplements, and the science of longevity (Diary of a CEO, 2026):

Notable adoption. David Sinclair disclosed in his March 2026 Diary of a CEO interview that he takes 500mg fisetin daily as part of his updated longevity protocol, citing its senolytic and anti-inflammatory properties.

Where the Science Stands

Fisetin's evidence base is honestly described as: ironclad animal model data, clear mechanistic evidence in human cells, early-stage human safety data, and multiple Phase 2 clinical trials actively underway. The definitive human efficacy data – from AFFIRM-LITE – is what the field is waiting for.

This is not a weakness to hide. It is the honest frontier of the science. The Mayo Clinic – one of the most conservative medical institutions in the world – is running multiple human trials on fisetin. That tells you what the researchers closest to the data believe about its potential.

Citations:

• Yousefzadeh MJ et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018. PMC6197652
• Baker DJ et al. Clearance of p16-positive senescent cells delays ageing-associated disorders. Nature. 2011. PMID 22048312
• Baker DJ et al. Naturally occurring p16-positive cells shorten healthy lifespan. Nature. 2016. PMID 26840489
• Murray et al. Intermittent fisetin supplementation. Aging Cell. 2025. PMC12341784
• Raut PK et al. Enhanced bioavailability of fisetin. Journal of Nutritional Science. 2022. PMC9574875
• Fisetin COVID safety trial. J Am Geriatr Soc. 2021. PMID 34375437

Frequently Asked Questions

Q: What is fisetin and what does it do?

Fisetin is a naturally occurring flavonoid found in strawberries, apples, and onions. It is classified as a senolytic – a compound that selectively clears senescent ("zombie") cells by disrupting the PI3K/AKT/BCL-2 survival pathway these cells depend on. It also provides anti-inflammatory, antioxidant, and neuroprotective benefits through NF-κB inhibition and Nrf2 activation.

Q: What foods contain fisetin?

Strawberries are the richest dietary source (160 μg/g), followed by apples, persimmons, onions, and cucumbers. However, dietary amounts are far below the doses studied for senolytic activity. A 200 mg supplemental dose of encapsulated fisetin is equivalent to approximately 1.25 kg of strawberries – and delivers 26.9x more to your bloodstream due to microencapsulation.

Q: Is fisetin safe?

Multiple safety studies, including a trial in elderly frail patients (PMID 34375437), show fisetin is well-tolerated. It has been studied at doses up to 20 mg/kg/day in clinical trials without significant adverse events. As with all supplements, consult your healthcare provider before starting.

Q: How should fisetin be taken – daily or in cycles?

Both approaches have merit. Daily low-dose supplementation (200 mg) provides continuous anti-inflammatory and antioxidant benefits. A monthly higher-dose cycle (the "pulse" approach used in clinical trials) may offer additional senolytic activity by clearing accumulated senescent cells. A practical approach combines both: a daily dose plus an optional monthly surge protocol.

Q: What is the difference between fisetin and quercetin?

Both are senolytics, but fisetin ranked higher than quercetin in the Mayo Clinic flavonoid screen. They work through overlapping but distinct pathways and are often used together. Quercetin in phytosome form pairs well with fisetin for complementary senolytic activity and broader anti-inflammatory coverage.

Related Reading

• Senescent Cells Explained: The Zombie Cells Aging You Faster
• Senomorphics vs Senolytics: Two Strategies for Dealing With Zombie Cells
• Inflammaging: The Chronic Inflammation That Drives Every Aging Hallmark
• Autophagy Explained: Cellular Recycling, Fasting, Exercise, and Aging
• The 12 Hallmarks of Aging: Why You Age and What Targets Each One
• Apigenin: CD38 Inhibitor, Sleep Support, and NAD+ Protector

Daily Compounds – your habits are dialed. Your cells aren’t. Learn more →